Efficacité de l'éplérénone dans le traitement de la choriorétinite séreuse centrale : à propos de 15 cas.

Central serous chorioretinitis (CSCR) is a relatively common eye condition. It is a maculopathy of young subjects, characterized by the presence of a serous retinal detachment (SRD) usually located at the posterior pole, associated with changes in the pigment epithelium. It has been suggested that CSCR may result from hyperactivation of mineralocorticoid receptors in the choroidal vessels. We therefore evaluated the efficiency and safety of eplerenone, a mineralocorticoid receptor antagonist, in the treatment of chronic CSCR. In our retrospective study carried out at the Moulay-Ismail military hospital in Meknes, 15 patients with chronic CSCR evolving for more than 3 months were recruited. Treatment with Eplerenone (Inspra) 50 mg per day for the first month, then 25 mg per day for 2 months was prescribed. Our study included 15 eyes of 15 patients who were included, who presented with central serous chorioretinopathy. A significant decrease in central macular thickness between the initial measurement at the start of treatment with eplerenone, and the control at one month after treatment, then at the end of treatment where a complete disappearance of serous retinal detachment was noted. in 46.6% of our patients, or seven patients. As for visual acuity, a significant improvement was observed at 1 month (0.22) and 3 months (0.11). We were able to demonstrate the effectiveness of eplerenone with a significant improvement in visual acuity, central macular thickness and the size of serous retinal detachment. These encouraging results allow us to consider integrating Eplerenone into the already existing therapeutic arsenal. Thus, in our study, the introduction of eplerenone resulted in significant anatomical and functional improvement in patients with chronic CSCR. [ABSTRACT FROM AUTHOR]